洛铂联合吉西他滨治疗晚期胰腺癌临床观察

目的观察洛铂联合吉西他滨治疗晚期胰腺癌的t临床疗效及不良反应。方法30例晚期胰腺癌患者随机分为两组，观察组18例，给予GP方案（洛铂联合吉西他滨），21d为1个周期；对照组12例，给予GEMOX方案（奥沙利铂联合吉西他滨），21d为1个周期，均至少化疗2个周期。结果30例患者均可评价疗效和不良反应。观察组临床受益反应率明显优于对照组（53％vs32％，P〈0．05）；观察组中位生存期和1年生存率也明显优于对照组（P〈0．05）；主要不良反应（血小板减少、胃肠道反应、末梢神经炎）较对照组轻，其他不良反应两组相似，患者均可耐受。结论洛铂联合吉西他滨治疗晚期胰腺癌近期临床疗效较高，不良反应可以耐受。

Clinical observation of lobaplatin combined with gemcitabine in the treatment of advanced pancreatic cancer

Objective To observe the clinical efficacy and adverse reactions of lobaplatin（LBP） combined with gemcitabine in the treatment of advanced pancreatic cancer. Methods Thirty cases of advanced pancreatic cancer were randomly divided into two groups. The observation group with 18 pa- tients received GP program （lobaplatin and gemcitabine）, 21 days for 1 cycle; and the control group of 12 patients received GEMOX programs （oxaliplatin and gemcitabine）, 21 days for 1 cycle. Patients in the two groups received at least 2 cycles of chemotherapy. Results All 30 patients can be evaluated for efficacy and adverse reactions. Clinical benefit response rate of the observation group was significantly higher than the control group （53% vs 32%, P 〈 0. 05 ） ; median survival and 1 -year survival of the observation group was significantly better than the control group （P 〈 0.05 ） ; major adverse reactions （thrombocytopenia, gastrointestinal reactions, peripheral neuritis） were lighter than the control group, other adverse reactions were similar tolerable. Conclusions Lobaplatin （LBP） combined with gemcitabine in the treatment of advanced pancreatic cancer is effective, and the adverse reactions can be tolerated.